Charles River Laboratories International, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Birgit Girshick
- Full Time Employees
- 19,700
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 251 Ballardvale Street Wilmington MA United States 01887
- IPO Date
- Jun 23, 2000
- CIK
- 0001100682
- Website
- criver.com
- Similar Companies
- Business
- Charles River Laboratories International, Inc. (NYSE: CRL) provides essential drug discovery, non-clinical development, safety assessment, and manufacturing solutions to the pharmaceutical, biotechnology, and medical device industries worldwide. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company operates through three primary segments: Research Models and Services (RMS), which supplies research animal models including genetically modified rodents, preconditioned animals, and related services such as genetic monitoring and vivarium management; Discovery and Safety Assessment (DSA), which delivers early-stage discovery studies for target identification, compound validation, in vivo pharmacology, and comprehensive safety testing encompassing toxicology, pathology, bioanalysis, drug metabolism, pharmacokinetics, and safety pharmacology; and Manufacturing Solutions, which offers in vitro quality control testing for sterile and non-sterile pharmaceuticals and consumer products, specialized biologics testing, avian vaccine services including specific-pathogen-free eggs and chickens, and microbial solutions for endotoxin detection. With facilities spanning the United States, Europe, Canada, Asia Pacific, and other international regions, Charles River supports clients from concept to commercialization, including advanced modalities like cell and gene therapies through its integrated CDMO capabilities. Recent developments include a strategic exploration of collaboration with BioTech Social announced in late 2024 to integrate crowdfunding via the BioTech Funding Portal into its Charles River Incubator Program (CIP) and Cell and Gene Therapy Accelerator Program (CAP), both launched in 2024 to provide regulatory expertise, lab space, and funding pathways for early-stage developers; a $13 million expansion of its microbial solutions facility in Charleston County, South Carolina, in August 2025 to enhance quality control testing capacity; alliances with the Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles in 2025 to advance oncology manufacturing and Phase I clinical trial materials for pediatric solid tumors; renewal of its partnership with the CHDI Foundation to bolster Huntington's disease research; and ongoing portfolio enhancements in plasmid DNA, viral vectors, and cell therapy services to meet rising demand in advanced therapies.
Company News
Charles River Leverages Virtual Control Groups in GLP Studies
Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock
8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC
Ariel Fund Q3 2026 Leaders And Laggards
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average – Should You Sell?
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
PGNY or CRL: Which Is the Better Value Stock Right Now?
Charles River Gains 75.8% in a Year: What's Driving the Rally?
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)
PGNY vs. CRL: Which Stock Is the Better Value Option?
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript